AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for AEON Biopharma in a research report issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.29) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for AEON Biopharma's current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma's Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.71) earnings per share for the quarter.
AEON Biopharma Stock Down 3.7 %
Shares of AEON stock traded down $0.25 on Thursday, reaching $6.54. The company had a trading volume of 41,384 shares, compared to its average volume of 52,009. The business's 50-day moving average is $10.69 and its 200 day moving average is $7.78. AEON Biopharma has a one year low of $3.37 and a one year high of $17.17.
Hedge Funds Weigh In On AEON Biopharma
A number of institutional investors have recently added to or reduced their stakes in AEON. Northern Trust Corp grew its stake in shares of AEON Biopharma by 53.4% during the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company's stock worth $359,000 after buying an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new stake in AEON Biopharma during the 3rd quarter worth approximately $360,000. Vanguard Group Inc. bought a new stake in AEON Biopharma during the 3rd quarter worth approximately $1,085,000. Finally, Atalaya Capital Management LP acquired a new position in AEON Biopharma in the 3rd quarter valued at approximately $19,827,000. 22.78% of the stock is currently owned by institutional investors and hedge funds.
AEON Biopharma Company Profile
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Recommended Stories
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
